EUVIMEDScopri EUVIMED
Open access · CC BY-NC-ND 4.0

Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: Data of the European Soft Tissue Sarcoma Registry SoTiSaR

Amadeus T Heinz iD, Anton Schönstein, Martin Ebinger, Jörg Fuchs, Beate Timmermann, Guido Seitz, Christian Vokuhl, Marc Münter, Kristian W Pajtler, Sabine Stegmaier, Thekla von Kalle, Christian P Kratz and 6 more

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.30707 ↗

At a glance

Journal article in Pediatric Blood & Cancer, 2024. Written by Amadeus T Heinz and 17 co-authors. Institution: Department of Pediatric Hematology and Oncology, University Children´s Hospital Tuebingen, Tuebingen, Germany. Major MEDLINE topics: Rhabdomyosarcoma, Sarcoma, Rhabdomyosarcoma, Alveolar, Soft Tissue Neoplasms. Cited 19 times so far (Crossref); 39 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Deutsche Kinderkrebsstiftung, Bonn, Germany, Stiftung des Foerdervereins für Krebskranke Kinder Tübingen.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Outcome of primary metastatic rhabdomyosarcoma (RMS) is poor. Certain risk factors as fusion status, Oberlin score, and local treatment of primary tumor are known to influence prognosis. Procedure Patients with metastatic RMS were treated according to Cooperative Weichteilsarkom Studiengruppe (CWS) guidance with chemotherapy (CHT), radiotherapy (RT) excluding total lung irradiation (TLI), complete resection of the primary tumor, and metastasectomy if possible. Kaplan–Meier estimators and Cox proportional hazard models were used to examine event‐free survival (EFS) and overall survival (OS) involving also landmark analyses.

Results

In the European Soft Tissue Sarcoma Registry SoTiSaR (2009–2018), 211 patients were analyzed. Many patients had fusion‐positive alveolar RMS ( n = 83; 39%). Median age was 9.4 years [0.1–19.7 years]. Treatment primarily consisted of CHT with CEVAIE (carboplatin, epirubicine, vincristine, actinomycin‐D, ifosfamide, etoposide: 86%, other regimens: 14%), RT (71%), resection of primary tumor (37%), metastasectomy (19%), and lymph node sampling/dissection (21%). Maintenance treatment (MT) (oral trofosfamide, idarubicin, etoposide) was added in 74% of patients. Oberlin factors, fusion status, and MT were predictive for EFS and OS. MT with O‐TIE was not improving outcome when adjusting for the immortal time bias. Local treatment of the primary tumor and radical irradiation (except TLI) improved EFS, not OS, when adjusting for the Oberlin score. Patients with fusion‐negative alveolar RMS ( n = 9) had an excellent outcome with a 5‐year EFS and OS of 100%, compared to patients with embryonal RMS (49%/62%), PAX7‐ (22%/47%) and PAX3/FOXO1‐positive ARMS (10/13%), respectively ( p < .001).

Conclusions

Prognosis of metastatic RMS primarily depends on fusion status and Oberlin score. Fusion status needs to be considered in future trials to optimize treatment outcome. The role of radical irradiation needs further investigation.

Subjects

MeSH terms (MEDLINE)

RhabdomyosarcomaSarcomaRhabdomyosarcoma, AlveolarSoft Tissue NeoplasmsChildHumansAdolescentEtoposideRisk FactorsAntineoplastic Combined Chemotherapy ProtocolsRegistries

Author keywords

Oberlin scorefusion statuslocal treatmentmetastatic diseasepediatric/adolescent oncologyrhabdomyosarcoma

Substances

Etoposide

Authors and institutions

  • Department of Pediatric Hematology and Oncology, University Children´s Hospital Tuebingen, Tuebingen, Germany.
  • Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin (Olgahospital), Pädiatrie 5 (Pädiatrische Onkologie, Hämatologie, Immunologie), Klinikum der Landeshauptstadt Stuttgart, Stuttgart, Germany.
  • Network Aging Research, Heidelberg University, Heidelberg, Germany.
  • Department of Pediatric Surgery and Urology, University Children's Hospital, Tuebingen, Germany.
  • Department of Particle Therapy, West German Proton Therapy Centre Essen (WPE), University Medical Center Essen, West German Cancer Center (WTZ), German Cancer Consortium (DKTK), Essen, Germany.
  • Department of Pediatric Surgery and Urology, University Hospital Giessen-Marburg, Marburg, Germany.

ORCID profiles: Amadeus T Heinz

Funding

  • Deutsche Kinderkrebsstiftung, Bonn, Germany
  • Stiftung des Foerdervereins für Krebskranke Kinder Tübingen

Cite

APA

Heinz, A. T., Schönstein, A., Ebinger, M., Fuchs, J., Timmermann, B., Seitz, G., Vokuhl, C., Münter, M., Pajtler, K. W., Stegmaier, S., von Kalle, T., Kratz, C. P., Ljungman, G., Juntti, H., Klingebiel, T., Koscielniak, E., Sparber-Sauer, M., & Cooperative Weichteilsarkom Studiengruppe (2024). Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: Data of the European Soft Tissue Sarcoma Registry SoTiSaR. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30707

Vancouver

Heinz AT, Schönstein A, Ebinger M, Fuchs J, Timmermann B, Seitz G, et al. Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: Data of the European Soft Tissue Sarcoma Registry SoTiSaR. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30707

BibTeX
@article{Heinz2024,
  author = {Heinz, Amadeus T and Schönstein, Anton and Ebinger, Martin and Fuchs, Jörg and Timmermann, Beate and Seitz, Guido and Vokuhl, Christian and Münter, Marc and Pajtler, Kristian W and Stegmaier, Sabine and von Kalle, Thekla and Kratz, Christian P and Ljungman, Gustaf and Juntti, Hanna and Klingebiel, Thomas and Koscielniak, Ewa and Sparber-Sauer, Monika and Cooperative Weichteilsarkom Studiengruppe, Cooperative Weichteilsarkom Studiengruppe},
  title = {Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: Data of the European Soft Tissue Sarcoma Registry SoTiSaR},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.30707}
}
Start for free →